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A kinetic analysis of the tyrosine-specific protein kinase of pp6O-Src from the C1300 mouse neuroblastoma
cell line Neuro-2A and pp6Oc-src expressed in fibroblasts was carried out to determine the nature of the
increased specific activity of the neuroblastoma enzyme. In immune-complex kinase assays with
ATP-Mn2+ and the tyrosine-containing peptide angiotensin I as phosphoacceptor substrate, pp6O-src from
the neuroblastoma cell line was characterized by a maximum velocity ( Vmax) that was 7-15-fold greater than
the Vmax. of pp60e-src from fibroblasts. The neuroblastoma enzyme exhibited Km values for ATP (16 + 3 /uM)
and angiotensin I (6.8 + 2.6 mM) that were similar to Km values for ATP (25 + 3 J#M) and angiotensin I
(6.5 + 1.7 mM) of pp60osrc from fibroblasts. pp6ov-src expressed in Rous-sarcoma-virus-transformed cells
exhibited an ATP Km value (25 + 4/M) and an angiotensin I Km value (6.6 + 0.5 mM) that approximated the
values determined for pp6o-src in neuroblastoma cells and fibroblasts. These results indicate that the
pp6Oc-src kinase from neuroblastoma cells has a higher turnover number than pp6c-src kinase from
fibroblasts, and that the neural form of the enzyme would be expected to exhibit increased catalytic activity
at the saturating concentrations of ATP that are found intracellularly.
INTRODUCTION
Proto-oncogenes are intensively studied because of
their presumed roles in normal cell growth and develop-
ment, in addition to their potential role in helping
understand the processes of cell transformation. The
function of the cellular src (c-src) proto-oncogene is
unknown, but several lines of evidence point to a role in
neuronal cells. The protein product of c-src is a 63 kDa
protein (pp6o0-src) with tyrosine-specific protein kinase
activity [1-3]. pp6O-src is preferentially synthesized in
neural tissues, with highest concentrations expressed in
embryonic neural retina and brain [4,5]. In neural retina
and cerebellum pp6Oc-src is expressed in neuronal cells at
the onset of terminal differentiation when proliferation
ceases, suggesting a role more closely linked to differen-
tiation or function of neuronal cells than proliferation
[6,7]. Immunocytochemical localization studies of
pp6Oc-src in sensory neurons ofchick dorsal-root ganglion
cultures [8] and biochemical identification of pp6Oc-src in
primary neuronal cultures from rat cerebral cortex [9]
confirm that pp6Oc-src is a product of neuronal cells.
However, pp6o0-src is not restricted to neurons, as it is
also expressed in neuroectodermal cells of early embryos
[10], fibroblasts [1,11,12] and astroglial-cell cultures [9].
It has been established that the pp6oc-src protein kinase
in neurons and neuroblastoma cells has an increased
specific activity compared with pp60-src in fibroblasts
and glial cells. Primary cultures of rat cortical neurons
express a structurally modified form of pp60ocsrc with
specific kinase activity 6-12-fold greater than astrocytes
from the same tissue, measured in the presence of
subsaturating substrate concentrations [9]. Human neuro-
blastoma cell lines also produce a form of pp6Oc-src with
a 20-40-fold higher specific tyrosine kinase activity than
that of pp6Ocsrc human glioblastoma cell lines or
fibroblasts [13].
To investigate the basis for the higher pp6Oc-sr kinase
specific activity in cells of neural origin, we carried out a
kinetic analysis of the protein kinase activity of pp6ocsrc
from the Cl300 mouse neuroblastoma cell line Neuro-
2A and a mouse fibroblast line that overexpresses
pp6Oc-src. The Neuro-2A cell line is a clone derived from
the spontaneously arising mouse neuroblastoma C1300
of sympathetic origin [14-16] that maintains differenti-
ated neuronal functions, as indicated by neuronal
morphology and expression of tyrosine hydroxylase [17].
The NIH(pMcsrc/cos)A cell line is a clone of NIH 3T3
mouse fibroblasts that overexpresses pp60'src from a
cloned chicken c-src gene introduced into the cells by
transfection [18]. We demonstrate in the present paper
that pp6Oc-src from the neuroblastoma cell line is a
tyrosine-specific protein kinase, whose phosphotrans-
ferase activity is characterized by a V..ax that is 7-15-fold
higher than that of pp6Oc-src in the fibroblast cell line with
only minor differences in Km values for the phospho-
donor or phospho-acceptor substrates. These results
suggest that the neural form of pp60c-src has a higher
turnover number, allowing it to operate with enhanced
catalytic efficiency even at the saturating concentrations
of ATP present in cells.
EXPERIMENTAL
Cell culture and method of extraction
The mouse C1300 neuroblastoma Neuro-2A cell line
was obtained from the American Type Culture Collection
(Rockville, MD, U.S.A.). The NIH(pMcsrc/cos)A cell
line was obtained from David Shalloway (Pennsylvania
State University). The RR1022 cell line (American Type
Culture Collection) is a rat tumour cell expressing the
product of the src gene of Rous sarcoma virus (Schmidt-
Ruppin strain). Neuro-2A neuroblastoma cells were
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grown in 100 mm-diam. tissue-culture plates to 80%
confluence for no more than seven passages in Dulbecco's
modified Eagle's medium containing 4.5 mg of glucose/
ml, 15 mM-Hepes, 50,tg of gentamicin/ml and 10%
(v/v) fetal-calf serum (KC Biologicals, Lenexa, KS,
U.S.A.) at 37 °C in a C02/air (1:19) atmosphere.
NIH(pMcsrc/cos)A and RR1022 cells were grown under
the same conditions, substituting 5 % calf serum (KC
Biologicals) for fetal-calf serum.
For preparation of extracts, cells in tissue-culture
dishes were washed three times in 0.15 M-NaCl/10 mM-
potassium phosphate buffer, pH 7.0, and were lysed at
4 °C in I ml of lysis buffer, which contained 20 mM-
potassium phosphate buffer, pH 7.0, 1 % (v/v) Nonidet
P-40, 0.5% (w/v) sodium deoxycholate, 0.15 M-KCI,
2 mM-sodium EDTA, 10 mM-NaF, I mM-sodium ATP,
200 /uM-sodium orthovanadate, 100 kallikrein-inhibitor
units of aprotinin/ml and 2 mm EGTA or 0.01 % (w/v)
leupeptin (Sigma Chemical Co.). After 20 strokes in a
Dounce homogenizer, lysates were centrifuged at
10000 g for 30 min and the supernatants retained. The
resulting cell extracts were stored at -70 'C. No change
in protein kinase activity resulted from storage at
-70 'C. Protein concentrations were determined by
the Lowry method [19].
Immune-complex protein kinase assays
pp6Oc-src phosphotransferase activity was determined
by the immune-complex protein kinase assay with
human angiotensin I acetate salt (Sigma Chemical Co.)
as phospho-acceptor substrate and [y-32P]ATP-Mn2' as
phospho-donor. pp60`src was immunoprecipitated from
cell extracts under conditions of antibody excess with
mouse monoclonal antibody 327 [20]. This antibody was
raised against bacterially expressed pp60-src and was
obtained from Joan Brugge (State University of New
York at Stony Brook). Monoclonal antibody 327
recognizes specifically the avian and mammalian forms
of pp60c-src in normal uninfected cells, and pp60v-src in
RSV-transformed cells [20]. Cell extracts (1.4 mg in I ml
of lysis buffer) were incubated for 2 h at 4 'C with 2 jul of
ascites fluid (0.1 mg/ml) containing monoclonal antibody
327. Then 50 #1 of 50% (v/v) goat anti-(mouse IgG)
antibody-agarose (Sigma Chemical Co.) in lysis buffer
was added to precipitate the immune complex. Immuno-
precipitates were centrifuged in a microcentrifuge and
washed four times in lysis buffer, once in 60 mM-Tris/
HCl buffer, pH 7.2, containing 2.5 M-KCI, 2 mM-sodium
EDTA, 10 mm-NaF, 50juM-sodium orthovanadate,
2 mm-EGTA and 100 kallikrein-inhibitor units of
aprotinin/ml, and twice in 20 mM-Tris/HCl buffer,
pH 7.2, containing 5 mM-MnCl2, 50,sM-sodium ortho-
vanadate, 100 kallikrein-inhibitor units of aprotinin/ml
and 0.1 % (w/v) leupeptin. For measurement of specific
activity, immunoprecipitates were divided into two equal
portions. One halfwas used to measure kinase activity in
the immune-complex protein kinase assay and the other
half was used for immunoblotting to determine the
amount of pp60cSI`c protein. For measurement of kinase
activity, the washed pellets were prewarmed to 30 'C and
protein kinase reactions were initiated by adding a
prewarmed solution (25 #I) composed of 20 mM-Tris/
HC1 buffer, pH 7.2, containing 5 mM-MnCl2, 5 mM-
dithiothreitol, 50 juM-sodium orthovanadate, 0.286 mCi
of [y-32P]ATP (86 Ci/mmol; New England Nuclear)/ml
and various concentrations of unlabelled sodium ATP
and angiotensin I, which were determined spectro-
photometrically. Reactions were carried out for 20 min at
30 'C. Pilot experiments, which were carried out with
pp60c-src from each cell type to establish initial-velocity
conditions, showed that angiotensin I phosphorylation
was linear with respect to time and extract concentration
for at least 30 min at 30 'C. Reactions were terminated
by chilling the tubes briefly on ice, centrifuging in a
microcentrifuge to remove immune complexes containing
the enzyme, and transferring supernatants to new tubes.
Phosphorylated angiotensin I in the supernatant was
separated from reactants by binding to Whatman P81
phosphocellulose paper under acidic conditions as
described by Glass et al. [21]. Briefly, 40 1l of 5% (w/v)
trichloroacetic acid was incubated with 20 F1 of the
supernatant containing phosphorylated angiotensin I for
10 min on ice. Samples (40 #z1) of the acidified solutions
were applied to 2 cm x 2 cm squares of Whatman P81
paper, washed three times in 0.425% (v/v) H3P04, dried,
and counted for 32P radioactivity in Omnifluor (Dupont)
in a scintillation counter.
To obtain the initial-velocity values (v) used for
determining kinetic constants, the total units of kinase
activity in the immunoprecipitates (pmol/min) were
divided by the relative amount of pp60csrc in the immune
complexes determined by immunoblotting. The amount
of pp60c-src in the immune complexes was quantified in
absorbance units by densitometric scanning of the
60 kDa band on autoradiograms of immunoblots de-
veloped with monoclonal antibody 327. Immunoblotting
of immunoprecipitates from neuroblastoma Neuro-2A
and NIH(pMcsrc/cos)A cell extracts was performed on
the same nitrocellulose filter to obtain absorbance units
reflecting the relative amounts of pp6o-Src protein.
Western iunoblotting
Washed immunoprecipitates were prepared as de-
scribed for the immune-complex protein kinase assay,
heated at 95 'C for 1 min in SDS sample buffer without
a thiol reducing agent, then centrifuged in a micro-
centrifuge. Supernatants were electrophoresed on 7.5%
polyacrylamide gels (9 cm) containing a 1/37 weight
ratio of bisacrylamide to acrylamide with the Laemmli
system [22]. Non-reducing conditions were used because
IgG heavy chains (53 kDa) are recognized by the 1251_
labelled secondary antibody, interfering with the detec-
tion of pp60c`c under reducing conditions. Proteins in
the gels were electroblotted on to a nitrocellulose
membrane (9 cm x 12 cm) (Millipore) [23]. The nitro-
cellulose blot was incubated with a 1:20 dilution of
monoclonal antibody 327 in a 0.8 ml volume of 50 mM-
Tris/HC1 buffer, pH 7.2, containing 150 mM-NaCl and
0.5% (v/v) Tween-20 (Sigma Chemical Co.) [24] for 1 h
at room temperature. The blot was washed five times
(200 ml) in the same buffer, incubated for 1 h at room
temperature with I /FCi of 1251-labelled anti-[mouse IgG
F(ab')2 fragment] antibody (5-20 Ci/mmol; Amersham/
Searle)/ml, washed as before and air-dried. l25l-labelled
pp60C arc bands were detected by autoradiography on
Dupont Cronex 6-plus X-ray film with Dupont Lightning
Plus intensifying screens and quantified with an LKB
2202 Ultrascan laser densitometer. The time of film
exposure was adjusted so that the intensity ofan exposed
region of film was within the linear range of response of
the film to 1251, as standardized previously [25].
Densitometric scanning of Western immunoblots
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Fig. 1. Lineweaver-Burk plot of pp601 tyrosine kinase activity
from neuroblastoma Neuro-2A and fibroblasts in
immune-complex protein kinase assays with various
concentrations of ATP and a fixed concentration of
angiotensin 1 (20 mM)
Initial velocity (v) indicates the number of pmol of
phosphate transferred to angiotensin I/min by an equal
amount of pp6Oc-src protein in the immune complexes from
extracts ofboth cell types. *, pp60Ocrc from neuroblastoma
Neuro-2A cells; 0, pp60c-src from NIH(pMcsrc/cos)A
fibroblasts.
showed that there was approx. 20-fold more pp60c-src in
immunoprecipitates from 1.4 mg ofNIH(pMcsrc/cos)A-
cell extract (14600 absorbance units/mg of extract
protein) compared with the neuroblastoma extract (714
absorbance units/mg ofextract protein). It was necessary
to employ a 20-fold difference in amount of pp60c-src
from the two cell types in the immune-complex protein
kinase assays to obtain approximately the same number
ofunits of protein kinase activity. This ensured reliability
in the measurements of total 32P radioactivity (c.p.m.)
transferred to angiotensin I at low ATP concentrations.
No difference in specific activity of pp60Ocsrc immuno-
precipitated from NIH(pMcsrc/cos)A-cell extracts
was observed when extract concentrations were varied
from 0.1 mg to 1.4 mg per ml of lysis buffer or when
Neuro-2A extract concentrations were varied from
0.7 mg to 1.4 mg per ml in immune-complex kinase
assays carried out at 20 ,uM-ATP-Mn2+ and 10 mm-
angiotensin I. The amount of pp60csrc determined by
immunoblotting was linear within this range of protein
concentrations.
Determination of enzyme kinetic constants
Km and Vmax values and their standard errors were
computed by the weighted least-squares method of
Wilkinson [26]. The initial velocities and Vma. values are
relative values expressed as pmol of phosphate trans-
ferred to angiotensin I/min by 1 absorbance unit of
pp6Oc-src. For determining background values, lysis
buffer was substituted for cell extract, and immune-
complex protein kinase assays were carried out at the
same fixed-substrate concentration and highest varied-
concentration-substrate concentration used in the assay.
Results of duplicate determinations were averaged and
background values subtracted. At 40 /LM-ATP the
amount of 32p transferred to angiotensin I in 20 min by
pp6O -src from the neuroblastoma Neuro-2A-cell extract
(1.4 mg) was 50710 c.p.m., of which 5650 c.p.m. repre-
sented the background. At 40 1M-ATP the amount of
32p transferred to angiotensin I in 20 min by pp6Oc-src
from the NIH(pMcsrc/cos)A-cell extract (1.4mg) was
61620 c.p.m., of which 5080 c.p.m. represented the
background.
RESULTS
To determine if pp60Oc-rc in mouse neuroblastoma
Neuro-2A cells exhibited elevated tyrosine protein kinase
activity, we determined Km and Vm.. values for ATP
and angiotensin I in immune-complex protein kinase
reactions catalysed by pp60Ocrc from neuroblastoma
Neuro-2A cells and from NIH(pMcsrc/cos)A fibroblasts.
These assays used monoclonal antibody 327 raised
against bacterially expressed pp60v-src that recognizes the
mammalian and avian forms of pp6OC-src in normal
untransformed cells [20]. pp6Oc-src was immunoprecipi-
tated from Neuro-2A-cell and NIH(pMcsrc/cos)A-cell
extracts containing the same amount and concentration
of protein. Phosphotransferase activity was measured
with ATP-Mn2+ as phospho-donor and synthetic human
angiotensin I peptide as phospho-acceptor substrate.
Western immunoblots of immunoprecipitates from both
cell types revealed a single major band at about 60 kDa,
the expected size of pp6O`Src.
In the first experiment Km and V.. values were
determined with various concentrations of ATP-Mn2+
and a fixed concentration ofhuman angiotensin I peptide
(20 mM) that was near saturating. Mn2" was used as
bivalent cation because the activity of pp60Oc-rc kinase
Table 1. Kinetic constants of pp601 kinase from neuroblastoma cells and fibroblass
Values for ATP were obtained at 20 mM-angiotensin I, and those for angiotensin I at 100 /zM-ATP-Mn2 . V.,.. is expressed as
pmol of phosphate transferred to angiotensin I/min by an equal amount of pp60c-src protein immunoprecipitated from Neuro-
2A-cell or NIH(pMcsrc/cos)A-cell extract as determined by Western immunoblotting. Values are given as means+S.E.M.
ATP Angiotensin I
Cell line Km (#M) V, Km (mm) VM=.
Neuroblastoma (Neuro-2A)
Fibroblast [NIH(pMcsrc/cos)AJ
16+3 273+23 6.8+2.6 357+59
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Fig. 2. Lineweaver-Burk plot of pp60w tyrosine kinase activity
from neuroblastoma Neuro-2A and fibroblasts in
immune-complex protein kinase assays with various
concentrations of angiotensin I and a fixed concentration
of ATP (100 FM)
Initial velocity (v) indicates the number of pmol of
phosphate transferred to angiotensin I/min by an equal
amount of pp60c-Src protein in the immune complexes from
extracts ofboth cell types. *, pp6Oc-src from neuroblastoma
Neuro-2A cells; 0, pp6oc-src from NIH(pMcsrc/cos)A
fibroblasts.
was found to be significantly greater with Mn2" than
Mg2+, in agreement with other reports [27]. Michaelis-
Menten plots of initial velocity (v) versus ATP
concentration ([S]) showed that pp6o src from neuro-
blastoma Neuro-2A cells and fibroblasts exhibited typical
saturation kinetics, with no observable allosteric effect
on kinase activity by ATP within the range of ATP
concentrations used. Lineweaver-Burk plots revealed
that pp6ocsrc kinase from Neuro-2A neuroblastoma cells
had a maximum velocity that was 7-fold greater than
that of pp6O src from fibroblasts (Fig. 1 and Table 1). In
contrast, only very slight differences in ATP Km values
were observed between pp6o src from neuroblastoma
cells (16 saM) and fibroblasts (25,UM) (Fig. 1 and
Table 1).
In the second experiment Km and Vmax values were
determined with various concentrations of angiotensin I
and a near-saturating concentration of ATP-Mn2+
(100 /IM). Michaelis-Menten plots of initial velocity (v)
versus angiotensin I concentration ([S]) showed that the
forms of pp60Ocsrc kinase from neuroblastoma Neuro-2A
cells and fibroblasts exhibited saturation kinetics with no
observable allosteric effect on kinase activity byangio-
tensin I. Lineweaver-Burk plots revealed no significant
difference in the angiotensin I Km values for pp6Ocsrc in
the two cell types (Fig. 2 and Table 1). The angiotensin
Km values were approx. 7 mm for pp60-src from both cell
types. At the near-saturating concentration of ATP used
in these experiments, the Vmax for pp60c-.rc from
neuroblastoma cells was approx. 15-fold greater than
that of pp60csrc from fibroblasts (Table 1), in accord
with the increased Vm.ax of pp60c-src from Neuro-2A cells
observed at the near-saturating concentration of angio-
tensin I (20 mM) used in the first experiment.
The Km values for pp608-,rc from Neuro-2A cells and
fibroblasts were similar to the Km values for ATP
(25 + 4 ftM) and angiotensin 1 (6.6 + 0.5 mM) exhibited by
the viral form of the enzyme (pp60v-src) expressed in the
Rous-sarcoma-virus-transformed cell line RR1022,
which was also determined with the use of monoclonal
antibody 327 in immune-complex protein kinase assays.
It was not possible to compare the Vmax values for
pp6OV-src with those of pp6Oc-src because monoclonal
antibody 327 did not efficiently recognize pp6Ov-src on
Western immunoblots of RR1022-cell extracts. The
amount of pp6Ov-src protein could not be reliably
compared with that of pp6Oc-src in the neuroblastoma
cells by metabolic labelling with [35S]methionine owing
to differential labelling of the viral and cellular forms of
the enzyme.
DISCUSSION
By the use of an immune-complex protein kinase assay
we show here that the pp6Oc-src tyrosine kinase in the
mouse neuroblastoma cell line Neuro-2A has a 7-15-fold
higher Vm.ax than the fibroblast enzyme, with only minor
differences in Km values for ATP and the phospho-
acceptor substrate. These results indicate that the
pp6Ocsrc kinase in neuroblastoma cells has a higher
turnover number, which would enable it to exhibit
enhanced catalytic activity even at the saturating con-
centrations of ATP found intracellularly.
The greater k,a, of the neuroblastoma enzyme appears
to be a general feature of pp6Oc-src in cells of neuronal
origin. The pp60c-src kinase from primary cultures of rat
cortical neurons exhibited 6-12-fold greater specific
activity than the enzyme in rat astrocyte cultures [9].
pp6O -src in human neuroblastoma cell lines shows a
20-40-fold increase in specific activity compared with the
enzyme in human glioblastoma cells or fibroblasts [13].
Because these studies were carried out in immune-
complex assays at a single subsaturating concentration
of ATP-Mg2+ (20 #SM [13]; 5 ,mU [9]), it was not possible
to predict whether differences in specific activity would
persist at the saturating concentrations of ATP that are
present in cells (2-3 mM) [28]. Our results showing that
pp60c-src from neuroblastoma Neuro-2A cells has an
increased Vm.ax at near-saturating concentrations ofATP
suggests that substrate may be turned over to product at
a greater rate by pp6Oc-src in neuroblastoma cells than by
pp60csrc in fibroblasts. An increased Vm.ax (5-20-fold)
has also been reported for pp60c-src bound to polyoma
middle T antigen [27].
The 7-15-fold increased Vmax of pp6Ocsrc kinase in
the Neuro-2A neuroblastoma cell line compared with
pp6O -src in NIH(pMcsrc/cos)A fibroblasts depends on
the relative amounts of pp6Oc-src protein measured. The
difference in amount of pp60'csrc protein in the two cell
lines was found to vary from 10- to 20-fold, as determined
by immunoblotting with monoclonal antibody 327.
Immunoblotting with a different monoclonal antibody,
AB src.1, showed 10-26-fold higher concentrations of
pp60c-src in the fibroblast cell line (results not shown).
Thus inaccuracy in measurement of pp60e-src protein in
immunoblotting could decrease the observed differences
in Vmax by 2.6-fold at most, in which case the
neuroblastoma enzyme would still exhibit a greater kcat.
The results reported here may be in error to the extent
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the two cell lines on immunoblots. However, they are in
accord with increased activity of the neuronal form of the
enzyme reported by others using [35S]methionine meta-
bolic labelling to measure pp6Oc-src protein. Differences
in metabolic labelling ofthe Neuro-2A and NIH(pMcsrc/
cos)A cell lines with [35S]methionine and lack of a
radioimmunoassay precluded measurement of pp6Oc-src
protein by an alternative method.
We do not know the nature of the modification
responsible for the greater kcat of pp60c-src in
neuroblastoma Neuro-2A cells. N-Terminal tyrosine
phosphorylation within the pp6Oc-src molecule has been
observed in human neuroblastoma cells [13], and an
unidentified N-terminal modification of pp6Oc-src not due
to tyrosine phosphorylation, that may be due to
alternative splicing, has been observed in neuronal
cultures [9]. However, in neither case has the modification
been shown to contribute to the activity of the kinase.
Several studies of pp60c-src from mouse fibroblasts have
demonstrated a correlation between dephosphorylation
of tyrosine-527, usually accompanied by increased
phosphorylation of tyrosine-416, and greater pp6Oc-src
protein kinase activity [29-33]. Cooper & King [29]
observed that dephosphorylation of pp6oc-src by phos-
phatase treatment in vitro caused a 10-20-fold increase
in pp6o0-src protein kinase activity that was attributable
to a decreased Km for ATP as well as an increased Vm.ax.
Similar C-terminal phosphorylations may play a role in
the regulation of pp6Oc-src protein kinase activity in
Neuro-2A cells.
The implications of the results reported here are
limited by the nature of the immune-complex protein
kinase assay, necessitated by the lack of purified pp6Ocsrc.
However; the ATP Km value for pp6O-,src from RR 1022
cells (25 /sM) obtained in the immune-complex protein
kinase assay with monoclonal antibody 327 approxi-
mated a reported ATP Km value (50 /LM) obtained with
purified pp6ov-src assayed in solution with [Val5]-
angiotensin II as phospho-acceptor substrate [34]. This
indicates that the kinase activity of pp6Oc-src in the
immune complex may not be affected by binding to the
monoclonal antibody.
The Km values for angiotensin I for pp6Ocsrc from
neuroblastoma Neuro-2A cells and fibroblasts were the
same, indicating that the phospho-acceptor sites of the
two forms of the enzyme were similar. It is possible that
differences at the phospho-acceptor site exist that were
not revealed by Km values for the peptide substrate, and
that differences in the Km might be found with phospho-
acceptor substrates other than angiotensin I. However,
in lieu of a physiological substrate, angiotensin I is
suitable for kinetic determinations, because it has a single
tyrosine residue. In vitro protein substrates such as o-
casein are likely to have multiple tyrosine residues that
can be phosphorylated by pp60c-src, rendering interpre-
tation of kinetic data difficult. Nonetheless, it will be
important to confirm the results presented here with
natural cellular substrates, once they are identified, and
also to determine if activation of pp6Ocsrc occurs in
neuroblastoma Neuro-2A cells in vivo.
The physiological role of the enhanced catalytic
efficiency of pp60-src kinase in neuroblastoma Neuro-2A
cells is not known. The greater kcat of pp6o-sru in Neuro-
2A cells does not appear to involve a genetic alteration of
c-src that is responsible for transformation of the
neuroblastoma cells. Transfection of NIH 3T3 cells with
Neuro-2A genomic DNA resulted in foci of transformed
cells whose DNA could be used in subsequent transfec-
tions to obtain secondary foci, indicating the presence of
a transforming gene (D. W. Fults & P. F. Maness,
unpublished work). DNA isolated from these secondary
foci did not contain multiple copies of the c-src gene
when analysed by Southern blotting. Moreover, extracts
of transformed cells from the secondary foci did not
exhibit elevated concentrations of pp6Oc-src on Western
blots or increased pp6Oc-src kinase activity in immune-
complex protein kinase assays, suggesting that the
transforming gene of Neuro-2A cells is not the c-src
gene.
The greater k,8, of pp6Ocsrc kinase from neuro-
blastoma cells appears instead to be a normal character-
istic of neuronal cells. The expression of pp6Ocsrc in
developing neurons of the neural retina and cerebellum is
maximal during the period of neurite outgrowth, and
immunoreactivity is concentrated in process-rich regions
[6,7]. In addition, the ability of pp60v-src to induce neurite
outgrowth in PC12 phaeochromocytoma cells implicates
tyrosine kinase activity in process formation and neur-
onal differentiation [35]. The increased catalytic efficiency
of pp6O-src protein kinase in neuroblastoma cells may
therefore be a manifestation of its activity in immature
neuronal cells, which could involve neurite extension or
some other aspect of neuronal differentiation.
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